Resistance of Akt kinases to dephosphorylation through ATP-dependent conformational plasticity

Phosphorylation of a threonine residue (T308 in Akt1) in the activation loop of Akt kinases is a prerequisite for deregulated Akt activity frequently observed in neoplasia. Akt phosphorylation in vivo is balanced by the opposite activities of kinases and phosphatases. Here we describe that targeting Akt kinase to the cell membrane markedly reduced sensitivity of phosphorylated Akt to dephosphorylation by protein phosphatase 2A. This effect was amplified by occupancy of the ATP binding pocket by either ATP or ATP-competitive inhibitors. Mutational analysis revealed that R273 in Akt1 and the corresponding R274 in Akt2 are essential for shielding T308 in the activation loop against dephosphorylation. Thus, occupancy of the nucleotide binding pocket of Akt kinases enables intramolecular interactions that restrict phosphatase access and sustain Akt phosphorylation. This mechanism provides an explanation for the “paradoxical” Akt hyperphosphorylation induced by ATP-competitive inhibitor, A-443654. The lack of phosphatase resistance further contributes insight into the mechanism by which the human Akt2 R274H missense mutation may cause autosomal-dominant diabetes mellitus.

[1]  D. M. Jacobsen,et al.  Briefly bound to activate: transient binding of a second catalytic magnesium activates the structure and dynamics of CDK2 kinase for catalysis. , 2011, Structure.

[2]  B. Brandhuber,et al.  Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition , 2010, PloS one.

[3]  Susan S. Taylor,et al.  A Transition Path Ensemble Study Reveals a Linchpin Role for Mg2+ during Rate-Limiting ADP Release from Protein Kinase A† , 2009, Biochemistry.

[4]  Jianpeng Ma,et al.  CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..

[5]  C. Schmidt,et al.  Resistance to Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitors Correlates with Up-Regulation of the MEK/Extracellular Signal-Regulated Kinase Pathway in Hepatocellular Carcinoma Cells , 2009, Journal of Pharmacology and Experimental Therapeutics.

[6]  P. Parker,et al.  PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity , 2009, Nature Structural &Molecular Biology.

[7]  Chao Zhang,et al.  Inhibitor Hijacking of Akt Activation , 2009, Nature chemical biology.

[8]  M. Czech,et al.  A PP2A Regulatory Subunit Regulates C. elegans Insulin/IGF-1 Signaling by Modulating AKT-1 Phosphorylation , 2009, Cell.

[9]  J. Kahana,et al.  AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. , 2009, Blood.

[10]  M. Laguerre,et al.  Role of a Novel PH-Kinase Domain Interface in PKB/Akt Regulation: Structural Mechanism for Allosteric Inhibition , 2009, PLoS biology.

[11]  Clive Wilson,et al.  The protein phosphatase PP2A-B′ subunit Widerborst is a negative regulator of cytoplasmic activated Akt and lipid metabolism in Drosophila , 2008, Journal of Cell Science.

[12]  S. Houser,et al.  Cardiac‐Restricted Overexpression of the A2A‐Adenosine Receptor in FVB Mice Transiently Increases Contractile Performance and Rescues the Heart Failure Phenotype in Mice Overexpressing the A1‐Adenosine Receptor , 2008, Clinical and translational science.

[13]  B. Zimmermann,et al.  Effect of metal ions on high-affinity binding of pseudosubstrate inhibitors to PKA. , 2008, The Biochemical journal.

[14]  Robert A Copeland,et al.  Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. , 2008, Cancer research.

[15]  W. Lee,et al.  Regulation of Phosphorylation of Thr-308 of Akt, Cell Proliferation, and Survival by the B55α Regulatory Subunit Targeting of the Protein Phosphatase 2A Holoenzyme to Akt* , 2008, Journal of Biological Chemistry.

[16]  Michael Keane,et al.  Characterization of a Protein Kinase B Inhibitor In Vitro and in Insulin-Treated Liver Cells , 2007, Diabetes.

[17]  T. Hunter,et al.  Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition , 2007, Oncogene.

[18]  B. Hemmings,et al.  Physiological roles of PKB/Akt isoforms in development and disease. , 2007, Biochemical Society transactions.

[19]  Ian Collins,et al.  A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. , 2007, Journal of molecular biology.

[20]  H. Huynh,et al.  Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma , 2007, Molecular Cancer Therapeutics.

[21]  Yan Shi,et al.  Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo , 2005, Molecular Cancer Therapeutics.

[22]  J. Sebolt-Leopold,et al.  A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. , 2005, Neoplasia.

[23]  J. Warmus,et al.  Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition , 2004, Nature Structural &Molecular Biology.

[24]  D. Dunger,et al.  A Family with Severe Insulin Resistance and Diabetes Due to a Mutation in AKT2 , 2004, Science.

[25]  B. Hemmings,et al.  Structure, regulation and function of PKB/AKT--a major therapeutic target. , 2004, Biochimica et biophysica acta.

[26]  P. Richardson,et al.  Pseudosubstrate peptides inhibit Akt and induce cell growth inhibition. , 2004, Biochemistry.

[27]  Brian A. Hemmings,et al.  Crystal structure of an activated Akt/Protein Kinase B ternary complex with GSK3-peptide and AMP-PNP , 2002, Nature Structural Biology.

[28]  R. Pearson,et al.  The synthetic peptide RPRAATF allows specific assay of Akt activity in cell lysates. , 2002, Analytical biochemistry.

[29]  V. Good,et al.  Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. , 2002, Molecular cell.

[30]  J. Kuriyan,et al.  The Conformational Plasticity of Protein Kinases , 2002, Cell.

[31]  T. Tsuruo,et al.  Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine) , 2002, Oncogene.

[32]  G. Panayotou,et al.  Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. , 2002, Cancer cell.

[33]  E. Degerman,et al.  Protein phosphatase 2A is the main phosphatase involved in the regulation of protein kinase B in rat adipocytes. , 2002, Cellular signalling.

[34]  A. Kowluru,et al.  Purine Nucleotide- and Sugar Phosphate-Induced Inhibition of the Carboxyl Methylation and Catalysis of Protein Phosphatase-2A in Insulin-Secreting Cells: Protection by Divalent Cations , 1998, Bioscience reports.

[35]  M. Kasuga,et al.  Requirement for Activation of the Serine-Threonine Kinase Akt (Protein Kinase B) in Insulin Stimulation of Protein Synthesis but Not of Glucose Transport , 1998, Molecular and Cellular Biology.

[36]  B. Burgering,et al.  Essential Role for Protein Kinase B (PKB) in Insulin-induced Glycogen Synthase Kinase 3 Inactivation , 1998, The Journal of Biological Chemistry.

[37]  M. Andjelkovic,et al.  Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Dixon,et al.  The phosphotyrosine phosphatase inhibitor vanadyl hydroperoxide induces morphological alterations, cytoskeletal rearrangements and increased adhesiveness in rat neutrophil leucocytes. , 1993, Journal of cell science.

[39]  B. Hemmings,et al.  Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway. , 2010, Current topics in microbiology and immunology.

[40]  J. Srivastava,et al.  Dephosphorylation of PKCdelta by protein phosphatase 2Ac and its inhibition by nucleotides. , 2002, FEBS letters.

[41]  P. Tsichlis,et al.  AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. , 1999, Annual review of biochemistry.

[42]  Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors , 2022 .